Treatment of myoclonic seizures

Expert Review of Neurotherapeutics

Volumn 12, Issue 12, 2012, Pages 1411-1418

  Striano, Pasquale ^a   Belcastro, Vincenzo ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b SANT ANNA HOSPITAL   (Italy)

Author keywords

antiepileptic drugs; clinical trials; epilepsy; myoclonic seizures; myoclonus; review; treatment

Indexed keywords

BENZODIAZEPINE; BRIVARACETAM; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; NITRAZEPAM; OXCARBAZEPINE; PHENYTOIN; PIRACETAM; PREGABALIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

AGGRESSIVENESS; AGITATION; ALZHEIMER DISEASE; BEHAVIOR DISORDER; CELIAC DISEASE; COGNITIVE DEFECT; CONFUSION; DIET THERAPY; DIPLOPIA; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; EPILEPTIC STATE; FOCAL EPILEPSY; HAPPY PUPPET SYNDROME; HUMAN; LENNOX GASTAUT SYNDROME; LIVER TOXICITY; LOW DRUG DOSE; MEMORY DISORDER; MENTAL DISEASE; MYOCLONIC ASTATIC EPILEPSY; MYOCLONUS EPILEPSY; MYOCLONUS SEIZURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SIDE EFFECT; SOMNOLENCE; TERATOGENICITY; TONIC CLONIC SEIZURE; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ANTICONVULSANTS; EPILEPSIES, MYOCLONIC; HUMANS;

EID: 84871092007     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.90     Document Type: Review

References (65)

1. Leppik IE. Classification of the myoclonic epilepsies. Epilepsia 44(Suppl. 11), 2-6 (2003). (Pubitemid 37385863)
2. Striano P, Zara F. Pathophysiology of myoclonic seizures. In: Atlas of Epilepsy. Panayiotopoulos CP (Ed.). Springer Science+Business Media, Berlin, 235-242 (2010).
3. Hirano Y, Oguni H, Funatsuka M, Imai K, Osawa M. Differentiation of myoclonic seizures in epileptic syndromes: a video-polygraphic study of 26 patients. Epilepsia 50(6), 1525-1535 (2009).
4. Cross E. Treatment of myoclonic epilepsies. Neurology Asia 9, 28-29 (2004).
5. Mikkelsen B, Birket-Smith E, Bradt S et al. Clonazepam in the treatment of epilepsy. A controlled clinical trial in simple absences, bilateral massive epileptic myoclonus, and atonic seizures. Arch. Neurol. 33(5), 322-325 (1976).
6. Browne TR. Clonazepam. A review of a new anticonvulsant drug. Arch. Neurol. 33(5), 326-332 (1976).
7. Obeso JA. Therapy of myoclonus. Clin. Neurosci. 3(4), 253-257 (1995).
8. Yamatogi Y, Ohtahara S, Shigematsu H, Oguni H, Nakashima M. Single-blind comparative study of clobazam with clonazepam in intractable childhood epilepsies. J. Japan Epilepsy Soc. 15, 110-121(1997). (Pubitemid 27294927)
9. Farrell K. Benzodiazepines in the treatment of children with epilepsy. Epilepsia 27(Suppl. 1), S45-S52 (1986).
10. Biton V, Sackellares JC, Vuong A, Hammer AE, Barrett PS, Messenheimer JA. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 65(11), 1737-1743 (2005).
11. Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure 5(2), 149-151 (1996). (Pubitemid 126687054)
12. Bergey GK. Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs. Epilepsia 46(Suppl. 9), 161-168 (2005). (Pubitemid 44921995)
13. Prasad A, Kuzniecky RI, Knowlton RC et al. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch. Neurol. 60(8), 1100-1105 (2003). (Pubitemid 36975798)
14. Marson AG, Al-Kharusi AM, Alwaidh M et al.; SANAD Study group. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369(9566), 1016-1026 (2007). (Pubitemid 46436125)
15. Tomson T, Battino D, Bonizzoni E et al.; EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 10(7), 609-617 (2011).
16. Morris GL, Hammer AE, Kustra RP, Messenheimer JA. Lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: results of an open-label study. Epilepsy Behav. 5(4), 509-512 (2004). (Pubitemid 39060706)
17. Cerminara C, Montanaro ML, Curatolo P, Seri S. Lamotrigine-induced seizure aggravation and negative myoclonus in idiopathic rolandic epilepsy. Neurology 63(2), 373-375 (2004). (Pubitemid 38971149)
18. Genton P, Gelisse P, Crespel A. Lack of efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht-Lundborg disease. Epilepsia 47(12), 2083-2085 (2006). (Pubitemid 44952261)
19. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 39(5), 508-512 (1998). (Pubitemid 28221807)
20. Striano P, Striano S, Minetti C, Zara F. Refractory, life-threatening status epilepticus in a 3-year-old girl. Lancet Neurol. 7(3), 278-284 (2008). (Pubitemid 351217099)
21. Crespel A, Genton P, Berramdane M et al. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology 65(5), 762-764 (2005). (Pubitemid 41285864)
22. Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann-Delgado J; N166 Levetiracetam Study Group. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 70(8), 607-616 (2008). (Pubitemid 351294638)
23. Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U; Levetiracetam N01057 Study Group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 69(18), 1751-1760 (2007). (Pubitemid 350059304)
24. Grunewald R. Levetiracetam in the treatment of idiopathic generalized epilepsies. Epilepsia 46, 154-160 (2005). (Pubitemid 44921994)
25. Labate A, Colosimo E, Gambardella A, Leggio U, Ambrosio R, Quattrone A. Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure 15(3), 214-218 (2006).
26. Specchio LM, Gambardella A, Giallonardo AT et al. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Res. 71(1), 32-39 (2006). (Pubitemid 44233197)
27. Specchio N, Boero G, Michelucci R et al. Effects of levetiracetam on EEG abnormalities in juvenile myoclonic epilepsy. Epilepsia 49(4), 663-669 (2008). (Pubitemid 351661065)
28. Belcastro V, Costa C, Galletti F, Rossi A, Tambasco N, Striano P. Rapid effect of levetiracetam in a case of juvenile myoclonic epilepsy. Epilepsy Behav. 14(1), 269-270 (2009).
29. Kasteleijn-Nolst Trenité DG, Hirsch E. Levetiracetam: preliminary efficacy in generalized seizures. Epileptic Disord. 5(Suppl. 1), S39-S44 (2003). (Pubitemid 36818443)
30. Kasteleijn-Nolst Trenité DG, Marescaux C, Stodieck S, Edelbroek PM, Oosting J. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res. 25(3), 225-230 (1996). (Pubitemid 26394544)
31. Striano P, Sofia V, Capovilla G et al. A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome). Epilepsia 49(3), 425-430 (2008). (Pubitemid 351294542)
32. Striano P, Coppola A, Pezzella M et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 69(3), 250-254 (2007). (Pubitemid 47205686)
33. Specchio N, Balestri M, Striano P et al. Efficacy of levetiracetam in the treatment of drug-resistant Rett syndrome. Epilepsy Res. 88(2-3), 112-117 (2010).
34. Striano P, Manganelli F, Boccella P, Perretti A, Striano S. Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov. Disord. 20(12), 1610-1614 (2005).
35. Delgado-Escueta AV, Enrile-Bacsal F. Juvenile myoclonic epilepsy of Janz. Neurology 34(3), 285-294 (1984). (Pubitemid 14173203)
36. Sundqvist A, Tomson T, Lundkvist B. Valproate as monotherapy for juvenile myoclonic epilepsy: dose-effect study. Ther. Drug Monit. 20(2), 149-157 (1998). (Pubitemid 28163196)
37. Atakli D, Sözüer D, Atay T, Baybas S, Arpaci B. Misdiagnosis and treatment in juvenile myoclonic epilepsy. Seizure 7(1), 63-66 (1998). (Pubitemid 28121952)
38. Kleveland G, Engelsen BA. Juvenile myoclonic epilepsy: clinical characteristics, treatment and prognosis in a Norwegian population of patients. Seizure 7(1), 31-38 (1998). (Pubitemid 28121947)
39. Bourgeois B, Beaumanoir A, Blajev B et al. Monotherapy with valproate in primary generalized epilepsies. Epilepsia 28(Suppl. 2), S8-S11 (1987). (Pubitemid 18035481)
40. Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia 23(6), 693-720 (1982). (Pubitemid 13184215)
41. Dulac O, Steru D, Rey E, Perret A, Arthuis M. Sodium valproate monotherapy in childhood epilepsy. Brain Dev. 8(1), 47-52 (1986). (Pubitemid 16080207)
42. Faught E, Wilder BJ, Ramsay RE et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology 46(6), 1684-1690 (1996). (Pubitemid 26185793)
43. Biton V, Montouris GD, Ritter F et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 52(7), 1330-1337 (1999). (Pubitemid 29190520)
44. Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A doubleblind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 52(9), 1882-1887 (1999). (Pubitemid 29260904)
45. Arroyo S, Dodson WE, Privitera MD et al.; EPMN-106/INT-28 Investigators. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol. Scand. 112(4), 214-222 (2005). (Pubitemid 41337067)
46. Nicolson A, Appleton RE, Chadwick DW, Smith DF. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J. Neurol. Neurosurg. Psychiatr. 75(1), 75-79 (2004). (Pubitemid 38091272)
47. Glauser TA, Pellock JM. Zonisamide in pediatric epilepsy: review of the Japanese experience. J. Child Neurol. 17(2), 87-96 (2002). (Pubitemid 34498435)
48. Kothare SV, Valencia I, Khurana DS, Hardison H, Melvin JJ, Legido A. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord. 6(4), 267-270 (2004). (Pubitemid 40095991)
49. Vossler DG, Conry JA, Murphy JV; ZNS-502/505 PME Study Group. Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study. Epileptic Disord. 10(1), 31-34 (2008). (Pubitemid 351507324)
50. Italiano D, Pezzella M, Coppola A et al. A pilot open-label trial of zonisamide in Unverricht-Lundborg disease. Mov. Disord. 26(2), 341-343 (2011).
51. Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev. 22(2), 75-80 (2000). (Pubitemid 30155631)
52. Wheless JW, Sankar R. Treatment strategies for myoclonic seizures and epilepsy syndromes with myoclonic seizures. Epilepsia 44(Suppl. 11), 27-37 (2003). (Pubitemid 37385866)
53. Dhamija R, Gavrilova RH, Wirrell EC. Valproate-induced worsening of seizures: clue to underlying diagnosis. J. Child Neurol. 26(10), 1319-1321 (2011).
54. Rubboli G, Tassinari CA. Negative myoclonus. An overview of its clinical features, pathophysiological mechanisms, and management. Neurophysiol. Clin. 36(5-6), 337-343 (2006). (Pubitemid 46320995)
55. Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia 42(6), 790-792 (2001). (Pubitemid 32605944)
56. Belcastro V, Arnaboldi M, Taborelli A, Prontera P. Induction of epileptic negative myoclonus by addition of lacosamide to carbamazepine. Epilepsy Behav. 20(3), 589-590 (2011).
57. Genton P, McMenamin J. Summary. Aggravation of seizures by antiepileptic drugs: what to do in clinical practice. Epilepsia 39(Suppl. 3), S26-S29 (1998). (Pubitemid 28215212)
58. Harding W, Jeavons J. Photosensitive epilepsy. Harding W, Jeavons J (Eds). MacKeith Press, London 125-150 (1992).
59. Errichiello L, Pezzella M, Santulli L et al. A proof-of-concept trial of the whey protein alfa-lactalbumin in chronic cortical myoclonus. Mov. Disord. 26(14), 2573-2575 (2011).
60. Hartman AL. Does the effectiveness of the ketogenic diet in different epilepsies yield insights into its mechanisms? Epilepsia 49(Suppl. 8), s53-s56 (2008).
61. Nangia S, Caraballo RH, Kang HC, Nordli DR, Scheffer IE. Is the ketogenic diet effective in specific epilepsy syndromes? Epilepsy Res. 100(3), 252-257 (2012).
62. Smith B, Shatz R, Elisevich K, Bespalova IN, Burmeister M. Effects of vagus nerve stimulation on progressive myoclonus epilepsy of Unverricht-Lundborg type. Epilepsia 41(8), 1046-1048 (2000). (Pubitemid 30640873)
63. Montouris G, Abou-Khalil B. The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent? Epilepsia 50(Suppl. 8), 16-20 (2009).
64. Auvin S, Chhun S, Berquin P, Ponchel E, Delanoë C, Chiron C. Aggravation of absence seizure related to levetiracetam. Eur. J. Paediatr. Neurol. 15(6), 508-511 (2011).
65. Bien CG, Schramm J. Treatment of Rasmussen encephalitis half a century after its initial description: promising prospects and a dilemma. Epilepsy Res. 86(2-3), 101-112 (2009).